author
necessarili
nh
nihr
depart
health
social
care
complet
list
investig
contributor
interv
trial
previous
provid
academ
coordin
centr
would
like
thank
blood
donor
centr
staff
blood
donor
particip
interv
trial
genotypetissu
express
gtex
project
support
common
fund
offic
director
nation
institut
health
nih
addit
fund
nation
cancer
institut
nation
human
genom
research
institut
nhgri
nation
heart
lung
blood
institut
nation
institut
drug
abus
nation
institut
mental
health
nation
institut
neurolog
disord
stroke
donor
enrol
biospecimen
sourc
site
fund
leido
biomed
inc
leido
subcontract
nation
diseas
research
interchang
roswel
park
cancer
institut
laboratori
data
analysi
coordin
center
ldacc
fund
contract
broad
institut
inc
biorepositori
oper
fund
leido
subcontract
van
andel
institut
addit
data
repositori
project
manag
provid
leido
author
would
like
thank
staff
iucpq
biobank
quebec
respiratori
heath
research
network
valuabl
assist
lung
eqtl
dataset
laval
univers
alreadi
known
topic
sever
acut
respiratori
syndrom
coronaviru
respons
current
coronaviru
diseas
covid
pandem
serin
proteas
involv
prime
spike
protein
cellular
entri
angiotensinconvert
enzym
receptor
express
lung
epithelium
might
implic
risk
infect
sever
studi
add
use
human
genet
variant
proxi
ace
inhibitor
drug
effect
cardiometabol
risk
factor
provid
insight
exposur
affect
lung
express
circul
level
find
support
hypothesi
ace
inhibitor
effect
express
found
support
associ
genet
liabil
type
diabet
mellitu
higher
lung
express
plasma
level
evid
inconsist
across
studi
object
use
human
genet
variant
proxi
angiotensinconvert
enzym
ace
inhibitor
drug
effect
cardiovascular
risk
factor
provid
insight
exposur
affect
lung
gene
express
circul
level
design
twosampl
mendelian
random
mr
analysi
set
summarylevel
genet
associ
data
particip
particip
predominantli
european
ancestri
variant
proxi
ace
inhibitor
drug
effect
cardiometabol
risk
factor
bodi
mass
index
chronic
obstruct
pulmonari
diseas
lifetim
smoke
index
lowdens
lipoprotein
cholesterol
systol
blood
pressur
type
diabet
mellitu
select
publicli
avail
genomewid
associ
studi
data
sampl
size
rang
particip
genet
associ
estim
lung
express
obtain
genetissu
express
gtex
project
particip
lung
eqtl
consortium
particip
genet
associ
estim
circul
plasma
level
obtain
interv
studi
particip
main
outcom
measur
lung
express
plasma
level
result
associ
genet
proxi
ace
inhibit
outcom
consid
evid
posit
associ
genet
liabil
type
diabet
mellitu
lung
gene
express
gtex
p
circul
plasma
level
interv
p
lung
express
lung
eqtl
consortium
studi
p
associ
genet
predict
level
cardiometabol
trait
outcom
conclus
studi
provid
evid
support
ace
inhibitor
antihypertens
drug
affect
lung
express
plasma
level
current
pandem
find
support
chang
ace
inhibitor
medic
use
without
clinic
justif
sever
acut
respiratori
syndrom
coronaviru
respons
current
coronaviru
diseas
pandem
serin
proteas
involv
prime
spike
protein
cellular
entri
angiotensinconvert
enzym
receptor
patient
frequent
present
respiratori
tract
infect
symptom
respiratori
failur
main
caus
death
follow
express
lung
epithelium
might
implic
risk
infect
sever
emerg
evid
suggest
patient
underli
cardiometabol
risk
factor
airway
diseas
like
suffer
sever
specul
angiotensinconvert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
class
antihypertens
medic
commonli
prescrib
patient
cardiometabol
risk
factor
might
affect
express
thu
affect
suscept
infect
sever
consequ
although
ace
dipeptidyl
carboxydipeptidas
distinct
physiolog
effect
ace
cleav
angiotensin
angiotensin
ii
consequ
activ
angiotensin
ii
receptor
type
pathway
result
vasoconstrict
inflamm
contrast
degrad
angiotensin
ii
angiotensin
angiotensin
angiotensin
angiotensin
activ
ma
receptor
vasodilatori
antiinflammatori
effect
anim
studi
support
effect
acei
arb
drug
express
activ
mix
find
associ
acei
arb
drug
use
activ
level
human
tissu
also
report
import
causal
effect
medic
cardiometabol
trait
express
investig
identif
mechanist
basi
exposur
affect
risk
sever
could
provid
use
insight
diseas
prevent
treatment
could
use
inform
optim
medic
use
strategi
shield
vulner
individu
well
improv
evid
base
public
health
campaign
mendelian
random
approach
use
genet
variant
relat
exposur
instrument
variabl
investig
effect
exposur
outcom
genet
variant
treat
analog
treatment
alloc
random
control
trial
typic
molecular
measur
gene
express
circul
protein
level
regard
mendelian
random
investig
exposur
variabl
follow
work
rao
lau
treat
molecular
measur
outcom
investig
aim
studi
appli
mendelian
random
investig
whether
gene
express
lung
circul
level
plasma
associ
genet
variant
ace
gene
region
consid
proxi
effect
acei
drug
genet
variant
relat
cardiometabol
risk
factor
genet
associ
exposur
variabl
two
differ
genet
instrument
proxi
acei
drug
effect
consid
first
select
singlenucleotid
polymorph
snp
ace
locu
associ
serum
ace
concentr
outcom
reduct
initi
glargin
intervent
origin
trial
strong
pairwis
correl
r
account
correl
variant
explain
varianc
serum
ace
concentr
secondli
select
singl
snp
locat
ace
locu
associ
systol
blood
pressur
sbp
p
studi
europeanancestri
individu
blood
pressur
lower
allel
snp
associ
reduct
sbp
snp
locu
associ
sbp
genomewid
level
signific
p
strong
pairwis
correl
r
index
variant
consid
six
cardiometabol
trait
exposur
variabl
bodi
mass
index
bmi
chronic
obstruct
pulmonari
diseas
copd
lifetim
smoke
index
lowdens
lipoprotein
cholesterol
ldlc
sbp
type
diabet
mellitu
trait
chosen
associ
prognosi
genet
associ
estim
exposur
obtain
publicli
avail
genomewid
associ
studi
gwa
summari
data
sourc
list
tabl
genet
variant
select
instrument
snp
associ
correspond
trait
genomewid
level
statist
signific
p
uncorrel
r
clump
correl
variant
perform
use
twosamplemr
packag
r
genet
associ
express
lung
tissu
obtain
two
sourc
genetissu
express
gtex
project
lung
eqtl
express
quantit
trait
loci
consortium
gtex
genet
associ
estim
obtain
individu
predominantli
european
ancestri
whole
genom
sequenc
perform
broad
institut
genom
platform
common
variant
minor
allel
frequenc
retain
genomewid
eqtl
analysi
perform
express
primari
tissu
sampl
taken
lung
genet
associ
imput
variant
across
autosom
chromosom
adjust
five
princip
compon
genotyp
data
probabilist
estim
express
residu
factor
sequenc
platform
illumina
hiseq
hiseq
x
sequenc
protocol
polymeras
chain
reactionbas
free
sex
gene
express
valu
sampl
normal
use
trim
mean
mvalu
method
edger
express
valu
normal
across
sampl
use
invers
normal
transform
lung
eqtl
consortium
genet
associ
estim
obtain
individu
european
ancestri
tissu
sampl
obtain
three
differ
institut
univers
british
columbia
laval
univers
univers
groningen
genomewid
eqtl
analysi
perform
express
use
probe
set
two
probe
set
subsequ
refer
particip
genotyp
use
illumina
human
duo
beadchip
genotyp
imput
use
haplotyp
refer
consortium
refer
panel
express
valu
first
standard
age
sex
smoke
statu
use
robust
linear
regress
genet
associ
estim
cohort
separ
use
linear
addit
genet
model
estim
combin
across
cohort
use
inversevari
weight
model
fixedeffect
genet
associ
estim
circul
plasma
level
obtain
subcohort
blood
donor
enrol
interv
bioresourc
plasma
level
measur
use
multiplex
proxim
extens
immunoassay
cardiovascular
panel
olink
bioscienc
uppsala
sweden
total
sampl
pass
qualiti
control
data
preprocess
use
standard
olink
workflow
includ
appli
median
centr
normal
across
plate
median
centr
overal
median
plate
follow
transform
provid
normal
protein
level
npx
npx
valu
regress
age
sex
plate
time
blood
draw
process
day
season
residu
rankinvers
normal
genotyp
data
process
describ
previous
genomewid
pqtl
analysi
perform
linear
regress
rankinvers
normal
residu
genotyp
snptest
first
three
compon
multidimension
scale
covari
adjust
ancestri
analysi
investig
genet
proxi
acei
drug
effect
use
variant
report
genet
associ
lung
express
plasma
level
per
blood
pressurelow
allel
mendelian
random
analys
estim
obtain
inversevari
weight
method
randomeffect
model
polygen
analys
base
ace
gene
locu
account
correl
variant
heterogen
mendelian
random
estim
differ
genet
variant
exposur
trait
express
use
statist
identifi
associ
p
weight
median
mregger
contaminationmixtur
method
robust
inclus
pleiotrop
variant
perform
sensit
analys
mendelian
random
estim
repres
chang
outcom
per
one
standard
deviat
increas
genet
predict
level
exposur
continu
exposur
trait
per
unit
increas
loge
odd
exposur
binari
trait
outcom
measur
rankbas
inversenorm
transform
chang
outcom
measur
standard
deviat
unit
data
use
work
obtain
publish
studi
obtain
relev
particip
consent
ethic
approv
variant
use
instrument
genet
associ
estim
select
publicli
avail
data
sourc
provid
supplementari
tabl
studi
protocol
detail
preregist
patient
public
involv
design
report
studi
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
result
analys
investig
genet
proxi
acei
drug
effect
display
figur
evid
associ
outcom
measur
analys
consid
variant
associ
serum
ace
figur
variant
associ
sbp
figur
main
inversevari
weight
method
mendelian
random
result
cardiometabol
risk
factor
display
figur
lung
express
plasma
concentr
figur
lung
express
evid
posit
associ
genet
liabil
lung
gene
express
gtex
p
circul
plasma
level
interv
p
supplementari
figur
similar
point
estim
obtain
perform
weight
median
mregger
contaminationmixtur
mendelian
random
sensit
analys
robust
presenc
pleiotrop
variant
although
confid
interv
wider
supplementari
tabl
mregger
method
identifi
evid
direct
pleiotropi
bias
analysi
supplementari
tabl
evid
associ
genet
liabil
lung
gene
express
lung
eqtl
consortium
p
evid
associ
genet
predict
level
cardiometabol
trait
gene
express
gtex
lung
eqtl
consortium
circul
plasma
level
interv
current
pandem
urgent
need
elucid
mechan
underli
risk
sever
view
inform
prevent
therapeut
strategi
studi
use
human
genet
variant
proxi
acei
drug
effect
cardiometabol
risk
factor
provid
insight
exposur
affect
lung
express
circul
level
find
associ
genet
proxi
ace
inhibit
lung
express
circul
plasma
level
result
therefor
provid
evid
support
acei
antihypertens
drug
affect
risk
sever
effect
express
previous
hypothesis
previous
identifi
chang
express
human
tissu
follow
acei
treatment
may
applic
lung
circul
plasma
level
find
support
stanc
profession
bodi
support
continu
acei
arb
antihypertens
drug
patient
unless
clinic
justif
stop
inde
appropri
use
medic
proven
benefit
abrupt
interrupt
also
consider
harm
also
specul
acei
arb
antihypertens
drug
might
reduc
sever
clinic
trial
explor
current
plan
find
also
consist
guidanc
patient
start
take
drug
class
unless
clinic
indic
result
identifi
inconsist
support
effect
liabil
lung
express
plasma
level
associ
genet
liabil
lung
express
gtex
project
previous
describ
howev
identifi
associ
genet
liabil
lung
express
lung
eqtl
consortium
discrep
may
attribut
differ
popul
consid
gtex
project
lung
eqtl
consortium
lung
eqtl
consortium
consid
lung
tissu
patient
requir
resect
surgeri
sampl
gtex
project
taken
healthi
tissu
deceas
donor
taken
togeth
result
provid
consist
support
effect
cardiometabol
trait
lung
express
plasma
level
associ
cardiometabol
trait
sever
could
attribut
altern
mechan
risk
factor
still
use
stratifi
patient
term
vulner
similarli
current
find
support
causal
effect
copd
smoke
lung
express
factor
may
still
use
inform
risk
model
sever
studi
number
strength
use
genet
variant
instrument
variabl
studi
effect
acei
drug
cardiometabol
risk
factor
therefor
abl
investig
causal
effect
express
lung
ace
level
plasma
acei
drug
effect
use
two
complementari
instrument
select
strategi
base
associ
variant
ace
locu
circul
serum
ace
level
sbp
respect
consist
find
approach
add
strength
conclus
mendelian
random
approach
better
abl
overcom
confound
revers
causat
bia
limit
causal
infer
convent
epidemiolog
approach
consid
independ
cohort
assess
lung
express
plasma
level
abl
explor
consist
result
conclus
therefor
less
vulner
fals
posit
find
studi
also
limit
investig
express
lung
circul
level
plasma
may
express
tissu
relev
risk
sever
similarli
cellular
may
differ
biolog
effect
circul
plasma
gwa
analys
lung
express
plasma
level
perform
accord
differ
protocol
may
therefor
directli
compar
avail
genet
instrument
arb
antihypertens
drug
class
abl
investig
precis
analys
also
limit
notabl
lifetim
smoke
index
result
widest
confid
interv
may
therefor
studi
suffici
power
exclud
clinic
relev
effect
exposur
genet
variant
use
instrument
variabl
may
pleiotrop
effect
affect
outcom
pathway
independ
exposur
proxi
bia
consequ
mendelian
random
estim
possibl
exclud
possibl
rel
low
heterogen
detect
mendelian
random
estim
produc
differ
variant
along
consist
observ
perform
analysi
method
robust
pleiotropi
suggest
unlik
major
sourc
bia
summari
mendelian
random
studi
identifi
consist
evid
support
acei
antihypertens
drug
cardiometabol
trait
affect
lung
express
plasma
level
find
therefor
support
deviat
exist
expert
consensu
guidelin
manag
hypertens
face
current
pandem
effort
made
scientist
news
media
ensur
specul
stori
littl
evidenti
support
propag
cardiometabol
risk
factor
use
stratifi
patient
term
vulner
data
provid
consist
support
express
repres
causal
mechan
underli
associ
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
figur
genet
associ
gene
express
lung
gtex
lung
consortium
circul
protein
level
plasma
interv
per
one
standard
deviat
increas
ace
concentr
confer
variant
ace
gene
b
per
blood
pressurelow
allel
variant
ace
gene
bottom
panel
two
set
result
express
lung
eqtl
consortium
refer
two
separ
probe
set
estim
gene
express
b
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
figur
mendelian
random
estim
chang
gene
express
lung
per
unit
increas
genet
predict
level
exposur
two
set
result
lung
eqtl
consortium
refer
two
separ
probe
set
estim
gene
express
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
